The Pharmaceutical Research and Manufacturers of America (PhRMA) today released new advertising as part of its “From Hope to Cures” campaign, highlighting the stories of rare blood and lung cancer survivors.
The newest video in the collection features Matt, who was diagnosed nearly seven years ago with advanced non-small cell lung cancer. When he was diagnosed, he was given a slim chance of living up to five years. However, today Matt continues to lead an active life due to recent advancements in targeted gene therapies and innovations in cancer medicines.
The latest print and digital ads feature Jamie, a vibrant woman diagnosed 15 years ago with chronic myelogenous leukemia (CML). Watching her son grow up was a primary focus for her, and she’s been able to continue to do that and so much more. Thanks to advancements in CML treatments, today she maintains her sense of humor and imparts an infectious joy on those who meet her.
Earlier this year, the first collection of digital and print ads was released featuring Rhys, a five-year-old living with type 1 diabetes and celiac disease. Unveiled alongside the advertising was a video, titled “We’re Fighting Back,” which features both Rhys and Jamie, as well as Jen, a researcher who wakes up every day working to find new treatments and cures for patients.
To view the multimedia release go to:
http://www.multivu.com/players/English/7738431-phrma-from-hope-to-cures/
The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running.
The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia).
To view the multimedia release go to:
http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
This February, the American Academy of Pediatric Dentistry (AAPD) is celebrating National Children’s Dental Health Month by hosting the Tournament of Tooth Care, showcasing how parents and caregivers can help their kids fend off the Mouth Monsters –a.k.a. tooth decay. Parents and caregivers can tune in to the Mouth Madness to learn how to help little teeth take on the Mouth Monsters one big game at a time.
“Tooth decay in children is a major health epidemic for adolescents across the country,” said Dr. Robert Delarosa, AAPD President. “National Children’s Dental Health Month is a great time for parents to keep their children’s dental health top of mind. Make it a priority this month to find a Dental Home – or home base – for your child’s oral health needs and be sure your next check-up is on the calendar.”
Tooth decay is one of the top chronic infectious diseases among children in the U.S. About 60 percent of children will have had tooth decay at some point by age five. More than 50 million school hours are missed every year by school-aged children in the U.S. due to dental visits or problems. And tooth decay isn’t just bad for oral health; children who develop tooth decay at a young age are at a greater risk for developing problems with oral and general health, as well as with educational and social development.
To view the multimedia release go to:
http://www.multivu.com/players/English/7750251-aapd-mouth-madness-dental-health/
With the onset of winter season in the country, breathing problems and respiratory diseases will also be on the rise. To ensure that patients with respiratory problems breathe with ease, a comprehensive patient Mobile App named “My Breathefree” has been launched as a virtual caregiver by ‘Breathefree’, a public service initiative by Cipla. This app is specifically designed for Indian conditions and is available on Google play store and iOS platform for all patients, caregivers and doctors.
One of the major chronic respiratory problems in the country is asthma and “My Breathefree” app will be a great help towards better asthma management and control. Asthma causes limitations in daily activities, loss of school and work days, lung function impairment, reduced quality of life and an adverse socioeconomic burden. However, if monitored and treated properly, asthmatics can control their disease and lead an absolutely normal and healthy life.
To view the multimedia release go to:
http://www.multivu.com/players/English/7562351-lung-care-asthma-mobile-app/
New Orleans is one of the country’s most culturally, architecturally, and musically interesting cities. It will serve as the picturesque backdrop for Team Challenge, the Crohn’s & Colitis Foundation of America’s (CCFA) endurance training and fundraising program, to take over the city on February 28, 2016 for the Rock ‘n’ Roll New Orleans Marathon, Half Marathon & 10k.
For the first time ever, Team Challenge is recruiting for participants to run through the Big Easy while raising critical funds and awareness of Crohn’s disease and ulcerative colitis. Collectively known as inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis are painful, medically incurable diseases that attack the digestive system. There are more than 1.6 million Americans living with these chronic, debilitating diseases.
“Team Challenge provides people with an opportunity to raise critical research dollars while training to do something that, for many people, they never imagined they’d be able to do,” said Craig Comins, vice president of Team Challenge. “It is inspiring to see a group of people come together, some who have these diseases and some who do not, united in the mission of finding a cure for Crohn’s disease and ulcerative colitis.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7512652-ccfa-team-challenge-recruit-nola/
The Leukemia & Lymphoma Society (LLS), the world’s leading voluntary non-profit dedicated to blood cancers, released 30 “proof points” - one for each day of September, Blood Cancer Awareness Month - to demonstrate its impact on the cancer landscape and progress towards a world without blood cancers.
LLS has invested more than $1 billion in research to advance breakthrough therapies and cures for blood cancer patients. In many cases, those treatments are now helping patients with other cancers and chronic diseases. Due to its focus on blood cancers, survival rates are improving. Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled and even quadrupled.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554851-lls-blood-cancer-awareness-month/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
Dr. Ksenia Sorokina from Russia
A healthy child means a healthy family- Targeting prevention of dermatitis and adherence to treatment
This project consists of providing training workshops for parents and children with chronic skin diseases and developing the first ever website to allow patients living in remote areas of the Russian Federation to access a consultation with a dermatologist, as well as attend online training seminars for people presenting chronic dermatitis and to increase adherence to therapy for patients as well as their parents, within four Russian territories.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Today, WebMD Health Corp. (NASDAQ: WBMD) launched WebMD Healthy Target, an integrated health improvement program that uses biometric device data from activity trackers, wireless scales and glucose meters to deliver tailored, physician-reviewed, contextually relevant content and motivational tips to individuals looking to develop sustainable health-conscious habits. WebMD Healthy Target will provide valuable assistance to individuals looking to manage chronic conditions like Type 2 diabetes and obesity, as well as to a broader audience interested in achieving their fitness goals or more generally living a healthier lifestyle.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/70402510-webmd-launches-health-improvement-program-for-iphone/
In honor of Fibromyalgia Awareness Day (May 12), this video illustrates the impact fibromyalgia pain has on various aspects of a person’s daily life – including relationships, work and other activities. It is based on a survey of more than 1,200 U.S. adults diagnosed with fibromyalgia. The survey was conducted in collaboration with the National Fibromyalgia & Chronic Pain Association (NFMCPA) and the American Association of Nurse Practitioners (AANP) and funded by Pfizer.
Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC.
The spot illustrates the struggles many people face when they are trying to lose or control their weight. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help some patients lose weight and keep it off.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7161051-eisai-launches-national-television-campaign-belviq-lorcaserin-hcl-civ
